Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01686607 · ClinicalTrials.gov registry record
Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents
A clinical trial of Systemic Fungal Infections, sponsored by Astellas Pharma Europe B.V..
- Completed
- Registry status
- 40,110
- Enrollment target
- 6
- Study locations
NCT01686607 is a study of Systemic Fungal Infections that has completed, run by Astellas Pharma Europe B.V.. The registered enrollment target is 40,110 participants. The trial reports 6 study locations across 5 states.
The verdict
NCT01686607, a study of Systemic Fungal Infections, has completed, sponsored by Astellas Pharma Europe B.V..
- COMPLETED
- Registry status
- 40,110 participants
- Enrollment target
- 6
- Study locations
Study Summary
This multicenter observational cohort study proposes to establish the risks of short and long-term outcomes in users of parenteral micafungin and in users of other parenteral antifungal agents from 2005 through 2012 with follow-up until 2017.
Conditions Studied
Interventions
- DRUG Parenteral micafungin application
- DRUG Other parenteral antifungal drugs
Study Locations (6)
Pennsylvania
- Site US5 - Philadelphia
- Site US1 - Pittsburgh
Maryland
- Site US4 - Baltimore
Massachusetts
- Site US2 - Boston
Michigan
- Site US6 - Ann Arbor
North Carolina
- Site US3 - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40,110 participants |
| Start Date | 2012-10-01 |
| Est. Completion | 2018-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01686607
The ClinicalTrials.gov registry entry for NCT01686607 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40,110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Europe B.V., which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Systemic Fungal Infections appearing as the primary indexed condition, and to 2 interventions - of which Parenteral micafungin application is the first listed.
NCT01686607 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Pennsylvania, Maryland, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01686607 about?
NCT01686607 is a clinical study titled "Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents". This multicenter observational cohort study proposes to establish the risks of short and long-term outcomes in users of parenteral micafungin and in users of other parenteral antifungal agents from 2005 through 2012 with follow-up until 2017.
What is the current status of trial NCT01686607?
This trial is currently completed. The enrollment target is 40,110 participants. The study started on 2012-10-01. Estimated completion is 2018-04-30.
What conditions does trial NCT01686607 study?
This clinical trial studies the following conditions: Systemic Fungal Infections.
What interventions are being tested in trial NCT01686607?
The interventions under investigation include: Parenteral micafungin application (DRUG), Other parenteral antifungal drugs (DRUG).
Who is sponsoring clinical trial NCT01686607?
This trial is sponsored by Astellas Pharma Europe B.V., which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01686607 being conducted?
This trial has 6 study locations across Maryland, Massachusetts, Michigan, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.